RVMD Revolution Medicines, Inc.

Nasdaq revmed.com


$ 54.89 $ -0.09 (-0.17 %)    

Monday, 20-Oct-2025 17:11:17 EDT
QQQ $ 612.11 $ 7.61 (1.26 %)
DIA $ 467.12 $ 5.24 (1.13 %)
SPY $ 671.75 $ 6.91 (1.04 %)
TLT $ 91.68 $ 0.35 (0.38 %)
GLD $ 401.36 $ 14.16 (3.64 %)
$ 54.01
$ 55.00
$ 54.08 x 50
$ 56.15 x 10
$ 53.47 - $ 55.28
$ 29.17 - $ 62.40
2,136,166
na
10.1B
$ 1.26
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2025 06-30-2025 10-Q
2 05-07-2025 03-31-2025 10-Q
3 02-26-2025 01-01-1970 10-K
4 11-06-2024 09-30-2024 10-Q
5 08-07-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 02-26-2024 12-31-2023 10-K
8 11-06-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-08-2023 03-31-2023 10-Q
11 02-27-2023 12-31-2022 10-K
12 11-07-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 02-28-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-11-2021 06-30-2021 10-Q
18 05-10-2021 03-31-2021 10-Q
19 03-02-2021 12-31-2020 10-K
20 11-12-2020 09-30-2020 10-Q
21 08-10-2020 06-30-2020 10-Q
22 05-14-2020 03-31-2020 10-Q
23 03-30-2020 12-31-2019 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 raymond-james-maintains-strong-buy-on-revolution-medicines-raises-price-target-to-76

Raymond James analyst Sean McCutcheon maintains Revolution Medicines (NASDAQ:RVMD) with a Strong Buy and raises the price ta...

 fda-unveils-first-experimental-drugs-under-fast-track-voucher-plan-to-cut-drug-review-times

The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, a...

 wedbush-reiterates-outperform-on-revolution-medicines-maintains-77-price-target

Wedbush analyst Robert Driscoll reiterates Revolution Medicines (NASDAQ:RVMD) with a Outperform and maintains $77 price target.

 no-need-to-sell-martin-marietta-materials-cramer-says-its-just-a-great-long-term-hold

Wells Fargo's Timna Tanners initiated coverage on Martin Marietta Materials with an Equal-Weight rating and announced a pri...

Core News & Articles

https://www.fda.gov/news-events/press-announcements/fda-awards-first-ever-national-priority-vouchers-nine-sponsors

 stifel-reinstates-buy-on-revolution-medicines-announces-85-price-target

Stifel analyst Laura Prendergast reinstates Revolution Medicines (NASDAQ:RVMD) with a Buy and announces $85 price target.

 goldman-sachs-maintains-buy-on-revolution-medicines-raises-price-target-to-73

Goldman Sachs analyst Andrea Newkirk maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target fro...

 raymond-james-assumes-revolution-medicines-at-strong-buy-announces-price-target-of-72

Raymond James analyst Sean McCutcheon assumes Revolution Medicines (NASDAQ:RVMD) with a Strong Buy rating and announces Pric...

 analysts-raise-price-targets-following-strong-data-from-revolution-medicines-pancreatic-cancer-drug

Revolution Medicines reports positive results from daraxonrasib trials in metastatic pancreatic cancer, with strong response ra...

 wedbush-maintains-outperform-on-revolution-medicines-raises-price-target-to-77

Wedbush analyst Robert Driscoll maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target f...

 wells-fargo-maintains-overweight-on-revolution-medicines-raises-price-target-to-70

Wells Fargo analyst Eva Fortea Verdejo maintains Revolution Medicines (NASDAQ:RVMD) with a Overweight and raises the price t...

 needham-maintains-buy-on-revolution-medicines-raises-price-target-to-66

Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $56 to $66.

 revolution-medicines-reports-daraxonrasib-results-in-metastatic-pancreatic-cancer-phase-3-trial-set-for-q4-2025

Long-term follow-up data for daraxonrasib monotherapy in second line metastatic pancreatic ductal adenocarcinoma reinforces pro...

 truist-securities-initiates-coverage-on-revolution-medicines-with-buy-rating-announces-price-target-of-99

Truist Securities analyst Asthika Goonewardene initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Buy rating an...

 piper-sandler-initiates-coverage-on-revolution-medicines-with-overweight-rating-announces-price-target-of-75

Piper Sandler analyst Kelsey Goodwin initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Overweight rating and a...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION